PDUFA Date

PDUFA Date: tividenofusp alfa

Indication
Hunter syndrome in January 2019

Other upcoming events for DNLI

Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in
Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tiv

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar